**Supplementary References**

1. Joesoef MR, Schmid GP, Hillier SL. Bacterial vaginosis: review of treatment options and potential clinical indications for therapy. Clin Infect Dis 1999; 28(Suppl 1):S57-S65.
2. Metronidazole vaginal gel, 0.75% prescribing information. Princeton, NJ: Sandoz Inc. 2016.
3. Bradshaw CS, Morton AN, Hocking J, et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis 2006; 193:1478-1486.
4. Marrazzo JM, Thomas KK, Fiedler TL, Ringwood K, Fredricks DN. Relationship of specific vaginal bacteria and bacterial vaginosis treatment failure in women who have sex with women. Ann Intern Med 2008; 149:20-28.
5. Turner AN, Carr Reese P, Fields KS, et al. A blinded, randomized controlled trial of high-dose vitamin D supplementation to reduce recurrence of bacterial vaginosis. Am J Obstet Gynecol 2014; 211:479.e1-479.e13.
6. Flagyl (metronidazole) tablets prescribing information. New York, NY: Pfizer Inc.; 2018.
7. Tindamax (tinidazole tablets) prescribing information. San Antonio, TX: Mission Phamacal Company; 2019.
8. Greaves WL, Chungafung J, Morris B, Haile A, Townsend JL. Clindamycin versus metronidazole in the treatment of bacterial vaginosis. Obstet Gynecol 1988; 72:799-802.
9. Cleocin HCl (clindamycin hydrochloride capsules) prescribing information. New York, NY: Pfizer Inc.; 2019.
10. Cleocin (clindamycin phosphate) vaginal cream prescribing information. New York, NY: Pfizer Inc.; 2019.
11. Cleocin vaginal ovules (clindamycin phosphate vaginal suppositories) prescribing information. New York, NY: Pfizer Inc.; 2018.
12. Livengood CH. Bacterial vaginosis: an overview for 2009. Rev Obstet Gynecol 2009; 2:28-37.
13. US Food and Drug Administration. Guidance for Industry: Bacterial Vaginosis: Developing Drugs for Treatment. 2016. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM510948.pdf. Accessed July 30, 2018.
14. Oduyebo OO, Anorlu RI, Ogunsola FT. The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women. Cochrane Database Syst Rev 2009; (3):CD006055.
15. Schwebke JR, Desmond RA. Tinidazole vs metronidazole for the treatment of bacterial vaginosis. Am J Obstet Gynecol 2011; 204:211.e1-211.e6.
16. Bohbot JM, Vicaut E, Fagnen D, Brauman M. Treatment of bacterial vaginosis: a multicenter, double-blind, double-dummy, randomised phase III study comparing secnidazole and metronidazole. Infect Dis Obstet Gynecol 2010; 2010. pii. 705692.
17. Schwebke JR, Morgan FG, Jr., Koltun W, Nyirjesy P. A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis. Am J Obstet Gynecol 2017; 217:678.e1-678.e9.
18. Hillier SL, Nyirjesy P, Waldbaum AS, et al. Secnidazole treatment of bacterial vaginosis: a randomized controlled trial. Obstet Gynecol 2017; 130:379-386.
19. Chavoustie SE, Gersten JK, Samuel MJ, Schwebke JR. A phase 3, multicenter, prospective, open-label study to evaluate the safety of a single dose of secnidazole 2 g for the treatment of women and postmenarchal adolescent girls with bacterial vaginosis. J Womens Health (Larchmt) 2018; 27:492-497.
20. Nyirjesy P, Schwebke JR. Secnidazole: next-generation antimicrobial agent for bacterial vaginosis treatment. Future Microbiol 2018; 13:507-524.
21. Faro S, Skokos CK, Clindesse Investigators G. The efficacy and safety of a single dose of Clindesse vaginal cream versus a seven-dose regimen of Cleocin vaginal cream in patients with bacterial vaginosis. Infect Dis Obstet Gynecol 2005; 13:155-160.
22. Chavoustie SE, Jacobs M, Reisman HA, et al. Metronidazole vaginal gel 1.3% in the treatment of bacterial vaginosis: a dose-ranging study. J Low Genit Tract Dis 2015; 19:129-134.
23. Schwebke JR, Marrazzo J, Beelen AP, Sobel JD. A phase 3, multicenter, randomized, double-blind, vehicle-controlled study evaluating the safety and efficacy of metronidazole vaginal gel 1.3% in the treatment of bacterial vaginosis. Sex Transm Dis 2015; 42:376-381.
24. Bradshaw CS, Sobel JD. Current treatment of bacterial vaginosis-limitations and need for innovation. J Infect Dis 2016; 214(Suppl 1):S14-S20.
25. Svare JA, Schmidt H, Hansen BB, Lose G. Bacterial vaginosis in a cohort of Danish pregnant women: prevalence and relationship with preterm delivery, low birthweight and perinatal infections. BJOG 2006; 113:1419-1425.
26. Martin HL, Richardson BA, Nyange PM, et al. Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. J Infect Dis 1999; 180:1863-1868.
27. Gillet E, Meys JF, Verstraelen H, et al. Association between bacterial vaginosis and cervical intraepithelial neoplasia: systematic review and meta-analysis. PLoS One 2012; 7:e45201.
28. Di Paola M, Sani C, Clemente AM, et al. Characterization of cervico-vaginal microbiota in women developing persistent high-risk Human Papillomavirus infection. Sci Rep 2017; 7:10200.
29. Bilardi JE, Walker S, Temple-Smith M, et al. The burden of bacterial vaginosis: women's experience of the physical, emotional, sexual and social impact of living with recurrent bacterial vaginosis. PLoS One 2013; 8:e74378.
30. Payne SC, Cromer PR, Stanek MK, Palmer AA. Evidence of African-American women's frustrations with chronic recurrent bacterial vaginosis. J Am Acad Nurse Pract 2010; 22:101-108.
31. Boris J, Pahlson C, Larsson PG. Six years observation after successful treatment of bacterial vaginosis. Infect Dis Obstet Gynecol 1997; 5:297-302.
32. Bradshaw CS, Brotman RM. Making inroads into improving treatment of bacterial vaginosis - striving for long-term cure. BMC Infect Dis 2015; 15:292.
33. McKinnon LR, Achilles SL, Bradshaw CS, et al. The evolving facets of bacterial vaginosis: implications for HIV transmission. AIDS Res Hum Retroviruses 2019; 35:219-228.
34. Marrazzo JM, Fiedler TL, Srinivasan S, et al. Extravaginal reservoirs of vaginal bacteria as risk factors for incident bacterial vaginosis. J Infect Dis 2012; 205:1580-1588.
35. Vrijens B, Urquhart J. Patient adherence to prescribed antimicrobial drug dosing regimens. J Antimicrob Chemother 2005; 55:616-627.
36. Eells SJ, Nguyen M, Jung J, Macias-Gil R, May L, Miller LG. Relationship between adherence to oral antibiotics and postdischarge clinical outcomes among patients hospitalized with *Staphylococcus aureus* skin infections. Antimicrob Agents Chemother 2016;60:2941-2948.
37. Machado D, Castro J, Palmeira-de-Oliveira A, Martinez-de-Oliveira J, Cerca N. Bacterial vaginosis biofilms: challenges to current therapies and emerging solutions. Front Microbiol 2015; 6:1528.
38. Fredricks DN, Fiedler TL, Thomas KK, Oakley BB, Marrazzo JM. Targeted PCR for detection of vaginal bacteria associated with bacterial vaginosis. J Clin Microbiol 2007; 45:3270-3276.
39. Verhelst R, Verstraelen H, Claeys G, et al. Cloning of 16S rRNA genes amplified from normal and disturbed vaginal microflora suggests a strong association between *Atopobium vaginae,* *Gardnerella vaginalis* and bacterial vaginosis. BMC Microbiol 2004; 4:16.
40. Fettweis JM, Brooks JP, Serrano MG, et al. Differences in vaginal microbiome in African American women versus women of European ancestry. Microbiology 2014; 160(Pt 10):2272-2282.
41. Ravel J, Gajer P, Abdo Z, et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci U S A 2011; 108(Suppl 1):4680-4687.
42. Verstraelen H, Verhelst R, Claeys G, De Backer E, Temmerman M, Vaneechoutte M. Longitudinal analysis of the vaginal microflora in pregnancy suggests that *L. crispatus* promotes the stability of the normal vaginal microflora and that *L. gasseri* and/or *L. iners* are more conducive to the occurrence of abnormal vaginal microflora. BMC Microbiol 2009; 9:116.
43. Laue C, Papazova E, Liesegang A, et al. Effect of a yoghurt drink containing *Lactobacillus* strains on bacterial vaginosis in women - a double-blind, randomised, controlled clinical pilot trial. Benef Microbes 2018; 9:35-50.
44. Bohbot JM, Darai E, Bretelle F, Brami G, Daniel C, Cardot JM. Efficacy and safety of vaginally administered lyophilized *Lactobacillus crispatus* IP 174178 in the prevention of bacterial vaginosis recurrence. J Gynecol Obstet Hum Reprod 2018; 47:81-86.
45. Bradshaw CS, Pirotta M, De Guingand D, et al. Efficacy of oral metronidazole with vaginal clindamycin or vaginal probiotic for bacterial vaginosis: randomised placebo-controlled double-blind trial. PLoS One 2012; 7:e34540.
46. Ya W, Reifer C, Miller LE. Efficacy of vaginal probiotic capsules for recurrent bacterial vaginosis: a double-blind, randomized, placebo-controlled study. Am J Obstet Gynecol 2010; 203:120 e121-126.
47. Nquqi BM, Hemmerling A, Bukusi EA, et al. Effects of bacterial vaginosis-associated bacteria and sexual intercourse on vaginal colonization with the probiotic *Lactobacillus crispatus* CTV-05. Sex Transm Dis 2011; 38:1020-1027.
48. Marrazzo JM, Dombrowski JC, Wierzbicki MR, et al. Safety and efficacy of a novel vaginal anti-infective, TOL-463, in the treatment of bacterial vaginosis and vulvovaginal candidiasis: a randomized, single-blind, phase 2, controlled trial. Clin Infect Dis 2019; 68:803-809.
49. Chavoustie SE, Carter BA, Waldbaum AS, et al. Two phase 3, double-blind, placebo-controlled studies of the efficacy and safety of astodrimer 1% gel for the treatment of bacterial vaginosis. Eur J Obstet Gynecol Reprod Biol. 2020; 245:13-18.
50. Broumas AG, Basara LA. Potential patient preference for 3-day treatment of bacterial vaginosis: responses to new suppository form of clindamycin. Adv Ther 2000; 17:159-166.
51. Hanson JM, McGregor JA, Hillier SL, et al. Metronidazole for bacterial vaginosis: a comparison of vaginal gel vs. oral therapy. J Reprod Med 2000; 45:889-896.
52. McGowan I, Gomez K, Bruder K, et al. Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004). AIDS 2011; 25:1057-1064.
53. Lam WY, Fresco P. Medication adherence measures: an overview. Biomed Res Int 2015; 2015:217047.
54. El Alili M, Vrijens B, Demonceau J, Evers SM, Hiligsmann M. A scoping review of studies comparing the medication event monitoring system (MEMS) with alternative methods for measuring medication adherence. Br J Clin Pharmacol 2016; 82:268-279.
55. Kardas P, Bishai WR. Compliance in anti-infective medicine. Johns Hopkins Adv Stud Med 2006; 6:S652-S658.